Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sunshine Biopharma (SBFM) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Sunshine Biopharma (SBFM) over the last 9 years, with Q3 2025 value amounting to 15.77%.

  • Sunshine Biopharma's EBITDA Margin fell 116700.0% to 15.77% in Q3 2025 from the same period last year, while for Sep 2025 it was 17.37%, marking a year-over-year decrease of 44400.0%. This contributed to the annual value of 19.1% for FY2024, which is 26100.0% down from last year.
  • Latest data reveals that Sunshine Biopharma reported EBITDA Margin of 15.77% as of Q3 2025, which was down 116700.0% from 7.29% recorded in Q2 2025.
  • Sunshine Biopharma's EBITDA Margin's 5-year high stood at 824.72% during Q4 2021, with a 5-year trough of 15445.58% in Q1 2021.
  • Its 5-year average for EBITDA Margin is 1651.92%, with a median of 24.23% in 2024.
  • As far as peak fluctuations go, Sunshine Biopharma's EBITDA Margin tumbled by -145844700bps in 2021, and later soared by 144384200bps in 2022.
  • Over the past 5 years, Sunshine Biopharma's EBITDA Margin (Quarter) stood at 824.72% in 2021, then tumbled by -172bps to 590.65% in 2022, then soared by 98bps to 9.88% in 2023, then plummeted by -233bps to 32.9% in 2024, then skyrocketed by 52bps to 15.77% in 2025.
  • Its EBITDA Margin stands at 15.77% for Q3 2025, versus 7.29% for Q2 2025 and 12.96% for Q1 2025.